These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33329783)

  • 21. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.
    Tuk B; Danhof M; Mandema JW
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):39-62. PubMed ID: 9353693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
    Keller F; Czock D; Zellner D; Giehl M
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous pharmacokinetic and pharmacodynamic modeling.
    Colburn WA
    J Pharmacokinet Biopharm; 1981 Jun; 9(3):367-88. PubMed ID: 7288596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
    Liu XY; Wang BJ; Yuan GY; Guo RC
    Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.
    Minto CF; Schnider TW; Egan TD; Youngs E; Lemmens HJ; Gambus PL; Billard V; Hoke JF; Moore KH; Hermann DJ; Muir KT; Mandema JW; Shafer SL
    Anesthesiology; 1997 Jan; 86(1):10-23. PubMed ID: 9009935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Closed-loop stability of pharmacokinetic-pharmacodynamic models.
    Wada DR
    Math Biosci; 1997 Dec; 146(2):75-88. PubMed ID: 9348740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.
    Schmidt H; Lötsch J
    Eur J Clin Pharmacol; 2007 Nov; 63(11):1045-54. PubMed ID: 17786418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Test hysteresis in pharmacokinetic/pharmacodynamic relationship with mixed-effect models: an instrumental model approach.
    Wang J; Li W
    J Biopharm Stat; 2014; 24(2):326-43. PubMed ID: 24605972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
    Csajka C; Verotta D
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles.
    Gabrielsson J; Jusko WJ; Alari L
    Biopharm Drug Dispos; 2000 Mar; 21(2):41-52. PubMed ID: 11100906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study.
    Gupta SK; Hwang SS; Benet LZ; Gumbleton M
    Pharm Res; 1993 Jun; 10(6):889-94. PubMed ID: 8321858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers.
    Yassen A; Olofsen E; Romberg R; Sarton E; Danhof M; Dahan A
    Anesthesiology; 2006 Jun; 104(6):1232-42. PubMed ID: 16732095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats.
    Visser SA; Smulders CJ; Reijers BP; Van der Graaf PH; Peletier LA; Danhof M
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1158-67. PubMed ID: 12183676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects.
    Zhou Y; Hu P; Huang Y; Nuoer S; Song K; Wang H; Wen J; Jiang J; Chen X
    Front Pharmacol; 2018; 9():1316. PubMed ID: 30510509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic modeling in vivo.
    Holford NH; Sheiner LB
    Crit Rev Bioeng; 1981; 5(4):273-322. PubMed ID: 7023829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.
    Cox EH; Knibbe CA; Koster VS; Langemeijer MW; Tukker EE; Lange R; Kuks PF; Langemeijer HJ; Lie-A-Huen L; Danhof M
    Pharm Res; 1998 Mar; 15(3):442-8. PubMed ID: 9563075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early phase pharmacokinetics but not pharmacodynamics are influenced by propofol infusion rate.
    Masui K; Kira M; Kazama T; Hagihira S; Mortier EP; Struys MM
    Anesthesiology; 2009 Oct; 111(4):805-17. PubMed ID: 19741485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simulating pharmacokinetic and pharmacodynamic fuzzy-parameterized models: a comparison of numerical methods.
    Seng KY; Nestorov I; Vicini P
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):595-621. PubMed ID: 17710517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
    Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.